Patents by Inventor Cecile Mannioui
Cecile Mannioui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11891614Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: May 17, 2020Date of Patent: February 6, 2024Assignee: CELLECTISInventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Patent number: 11603539Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: May 13, 2013Date of Patent: March 14, 2023Assignee: CELLECTISInventors: Roman Galetto, Agnès Gouble, Stéphanie Grosse, Cécile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Publication number: 20220348955Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: June 24, 2022Publication date: November 3, 2022Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Patent number: 11414674Abstract: A method of expanding deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: March 22, 2019Date of Patent: August 16, 2022Assignee: CELLECTISInventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Publication number: 20220177914Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: February 17, 2022Publication date: June 9, 2022Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Patent number: 11274316Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: March 11, 2021Date of Patent: March 15, 2022Assignee: CELLECTISInventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Publication number: 20210220405Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: March 11, 2021Publication date: July 22, 2021Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Publication number: 20200281979Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: May 17, 2020Publication date: September 10, 2020Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Patent number: 10517896Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: March 22, 2019Date of Patent: December 31, 2019Assignee: CELLECTISInventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Patent number: 10426795Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: May 13, 2013Date of Patent: October 1, 2019Assignee: CELLECTISInventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Patent number: 10363270Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: September 21, 2017Date of Patent: July 30, 2019Assignee: CELLECTISInventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Publication number: 20190216854Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: March 22, 2019Publication date: July 18, 2019Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Publication number: 20190216853Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: March 22, 2019Publication date: July 18, 2019Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Patent number: 10342829Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs. Such CARs, which aim to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties, comprise separate extracellular ligand binding and signaling domains in different transmembrane polypeptides. 91The signaling domains are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: September 4, 2013Date of Patent: July 9, 2019Assignee: CELLECTISInventors: Julianne Smith, Andrew Scharenberg, Cecile Mannioui, Justin Eyquem
-
Patent number: 10286007Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: July 26, 2017Date of Patent: May 14, 2019Assignee: CELLECTISInventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Publication number: 20180360883Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: July 5, 2018Publication date: December 20, 2018Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Publication number: 20180021379Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: September 21, 2017Publication date: January 25, 2018Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Publication number: 20170360835Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: July 26, 2017Publication date: December 21, 2017Inventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Publication number: 20150203817Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: May 13, 2013Publication date: July 23, 2015Applicant: CellectisInventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Publication number: 20150017136Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: July 15, 2013Publication date: January 15, 2015Applicant: CELLECTISInventors: ROMAN GALETTO, AGNÈS GOUBLE, STÉPHANIE GROSSE, CÉCILE MANNIOUI, LAURENT POIROT, ANDREW SCHARENBERG, JULIANNE SMITH